From The Director
- Outstanding research
- Expert clinical care
- Robust clinical trials
- Broad reach into the catchment area and across the nation
| 
These are the hallmarks of any cancer center truly committed to changing the trajectory of cancer for the better.
If you have visited the Myeloma Center at the UAMS Winthrop P. Rockefeller Cancer Institute, you have seen this commitment up close. Under the leadership of Frits van Rhee, M.D., Ph.D., our Myeloma Center continues to be the world’s leader in multiple myeloma treatment with the most advanced treatments, including cellular therapies for patients with relapsed disease. The myeloma clinical team is second to none and provides precision oncology for every patient. Their dedication to service is truly remarkable.
The myeloma program is equally impressive from a translational research standpoint. Fenghuang (Frank) Zhan, M.D., Ph.D., has built a spectacular research program that is clearly moving the field forward in identifying new therapeutic targets for multiple myeloma and new and novel agents. This continues to put the UAMS Myeloma Center as the key destination for myeloma patients.
Sincerely,
Michael Birrer, M.D., Ph.D.,
Vice Chancellor, University of Arkansas for Medical Sciences
Director, Winthrop P. Rockefeller Cancer Institute
Kent Westbrook, M.D., Director’s Chair, Winthrop P. Rockefeller Cancer Institute